Maarten van der Doelen
Patient-reported outcomes in mCRPC patients treated with radium-223 therapy
A
B
100
100
High baseline EORTC QLQ-C30 summary score Intermediate baseline EORTC QLQ-C30 summary score Low baseline EORTC QLQ-C30 summary score
90
90
80
80
70
70
60
60
50
50
40
40
30 Overall survival (%)
30 Overall survival (%)
20
20
10
10
0
0
0
6
12
18
24
30
36
42
48
54
0
6
12
18
24
30
36
42
48
54
Months since start of radium-223
Months since start of radium-223
Patients at risk Cohort 122
Patients at risk High 69 Intermed 40 Low 13
102
68
3
2
1
0
32
21
8
61 33
45 21
19 13
16 5 0
7 1 0
2 1 0
1 1 0
0 1 0
0 0 0
8
2
0
Supplementary figure 3. A . Overall survival of the total cohort. B . Overall survival stratified based on EORTC QLQ-C30 summary score categories at baseline.
4
Front
Back
most
least
Supplementary figure 4. Heat map of pain locations in metastatic castration-resistant prostate cancer patients prior to radium-223 therapy initiation (N=122). The color grid indicates the percentage of individuals that reported pain in the specific area. Dark red represents the most frequently reported area of pain, whereas white represents the least frequently reported area of pain.
111
Made with FlippingBook - professional solution for displaying marketing and sales documents online